A Multicenter, Open-label, Randomized, Prospective Clinical Study of Adebrelimab Consolidation Therapy for Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Without Progression After Concurrent Chemoradiotherapy
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study aims to evaluate the efficacy and safety of adebrelimab consolidation therapy after progression-free response of concurrent chemoradiotherapy in patients with limited-stage small cell lung cancer. This study plans to enroll patients with untreated limited-stage small cell lung cancer who meet the inclusion criteria. The eligible patients will be randomly divided 1:1 into two groups to receive treatment regimens for residual lymph nodes and involved irradiated areas. That is, carboplatin AUC 5, D1 + etoposide 100 mg/m…\^2 on days 1, 2, and 3 + thoracic radiotherapy (residual lymph nodes or involved irradiated areas), with each 3-week cycle. After 4 cycles of concurrent chemoradiotherapy, the non-progressing subjects will continue to receive adebrelimab (1200 mg, IV, Q3W) maintenance therapy.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18-75 lat, dowolnej płci
- •Potwierdzone histologicznie, do tej pory nieleczone stadium ograniczone raka płuca małokomórkowego (stadium I-III)
- •Pacjenci, którym nie można wykonać operacji lub ją odmawiają
- •Ogólny stan zdrowotny oceniany na 0-1 (w stanie do leczenia)
- •Spodziewana przeżywalność co najmniej 3 miesiące
- •Co najmniej jeden wymierny guz widoczny w badaniach obrazowych
- •Dostateczna funkcja płuc (wydychana objętość w 1 sekundzie >70% normy)
- •Prawidłowe wyniki badań krwi i funkcja wątroby oraz nerek
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- July 21, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Henan Cancer Hospital
Zhengzhou, China
Henan Cancer Hospital
Zhengzhou, China
Trial contact
Qingminf QM Wang, Professor
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/22/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.